December 6 - 8, 2022

Boston, Massachusetts. Jeff Lange, Virogin Biotech EVP Business Development, will present “New strategies for oncolytic virotherapy: turning anti-viral immunity to anti-tumor” at a session on Novel Combination Therapies to Maximize Anti-Cancer Effectiveness on December 6. 

October 24 - 26, 2022

Leipzig, Germany. Jeff Lange, Virogin Biotech EVP Business Development, will present an overview of Virogin Biotech and its OV platforms and will participate in one-to-one partnering meetings. 

October 23 - 26, 2022

Nagano, Japan. Dr. William Jia, Virogin Biotech CSO, will present “New strategies for oncolytic virotherapy: turning anti-viral immunity to anti-tumor” at a session on Novel Viral Platforms on October 24.